Postoperative mutant serum KRAS2, tumour KRAS2 status, and recurrence in group B
| Serum + (n (%)) | Recurrence rate (n (%)) | OR (95% CI) | p Value | |
|---|---|---|---|---|
| (+) and (−) refer to KRAS2 mutation status. †‡There was no significant difference in recurrence rates between tumour (+) and tumour (−) patients. | ||||
| ¶* In tumour (+) patients, disease recurrence was highly significantly increased in serum (+) compared with serum (−) patients. | ||||
| All group B patients (n=94) | 16 (17) | 20 (21) | ||
| Tumour + (n=60) | 16 (27) | 11 (18)‡ | 0.35‡ | |
| Tumour − (n=34) | 0 (0) | 9 (26) ‡ | ||
| Tumour +/serum + (n=16) | — | 10 (63)¶ | 71.6 (7.7–663.9)¶ | 0.0000¶ |
| Tumour +/serum – (n=44) | — | 1 (2)¶ | ||
| Group B subgroup only (n=85) | 15 (18) | 17 (20) | ||
| Tumour + (n=54) | 15 (28) | 10 (19)† | 0.65† | |
| Tumour − (n=31) | 0 (0) | 7 (23) † | ||
| Tumour +/serum + (n=15) | — | 9 (60)* | 57 (6.1–534.5)* | 0.0000* |
| Tumour +/serum − (n=39) | — | 1 (3)* | ||